Nanomedicine and Nanoscale Delivery (Focus Group – NND)
Banu Iyisan, PhD
Associate Professor
Bogazici University
Istanbul, Turkey
The development of cancer nanotherapeutics requires significant effort to achieve enhanced clinical outcomes. Nanocarriers must exhibit key properties, including biocompatibility, prolonged circulation time, targeted delivery, and high stability.1 Our strategy to improve these features involves tailoring biopolymers as stabilizers and shell materials to produce versatile hybrid nanocarriers with multiple capabilities.2,3 Here we report the design of albumin-hyaluronic acid (BSA-HA) coated lipid nanocarriers as multifunctional cancer therapeutics using surfactant-free, miniemulsion-templated methods.